| Diabetes Mellitus, Non-Insulin-Dependent
Janumet XR vs Tradjenta
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Janumet vs Tradjenta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTradjenta has a higher rate of injection site reactions vs Janumet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tradjenta but not Janumet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Janumet
Tradjenta
At A Glance
Oral
Once daily
DPP-4 inhibitor / biguanide
Oral
Daily
DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Take once daily with a meal; recommended starting dose is 100 mg sitagliptin and 1000 mg metformin HCl extended-release once daily; maximum daily dose is 100 mg sitagliptin and 2000 mg metformin HCl; dose of sitagliptin component limited to 50 mg once daily if eGFR falls below 45 mL/min/1.73 m2; do not split, crush, or chew tablets.
Diabetes Mellitus, Non-Insulin-Dependent 5 mg orally once daily, with or without food.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of a serious hypersensitivity reaction to JANUMET XR, sitagliptin, or metformin, such as anaphylaxis or angioedema
- Hypersensitivity to linagliptin or any excipient in TRADJENTA, including reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
Adverse Reactions
Most common (>=5%) Diarrhea, upper respiratory tract infection, headache (from sitagliptin and metformin coadministration studies); nasopharyngitis (sitagliptin monotherapy); hypoglycemia, diarrhea, nausea (extended-release metformin added to glyburide)
Serious Lactic acidosis, pancreatitis, heart failure, acute renal failure, vitamin B12 deficiency, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, hepatic enzyme elevations, fatal and non-fatal hemorrhagic and necrotizing pancreatitis, worsening renal function including acute renal failure, tubulointerstitial nephritis, severe and disabling arthralgia, bullous pemphigoid, constipation, vomiting, myalgia, rhabdomyolysis, cholestatic and hepatocellular liver injury
Most common (>=2%) Nasopharyngitis, diarrhea, cough
Serious Pancreatitis, hypoglycemia with concomitant insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid, rash
Pharmacology
JANUMET XR combines sitagliptin, a selective DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP) to increase insulin release and decrease glucagon in a glucose-dependent manner, and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity without altering insulin secretion.
DPP-4 inhibitor; linagliptin reversibly inhibits DPP-4, the enzyme that degrades incretin hormones GLP-1 and GIP, thereby increasing active incretin concentrations, stimulating glucose-dependent insulin release from pancreatic beta cells, and reducing glucagon secretion from pancreatic alpha-cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Janumet
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Tradjenta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Janumet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Tradjenta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Janumet
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Tradjenta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Janumet.
No savings programs available for Tradjenta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JanumetView full Janumet profile
TradjentaView full Tradjenta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.